Bristol Myers Squibb
Latest news, explainers and analysis on Bristol Myers Squibb. Tracking 2 stories on Arth Vani.
Connected in the graph
Latest on Bristol Myers Squibb
Bristol-Myers Squibb Stock Analysis: Is BMY Beating the Healthcare Sector?
Bristol-Myers Squibb (BMY) is showing signs of resilience as it attempts to outperform the broader healthcare sector. Investors are closely watching its valuation and dividend yield as the company navigates patent cliffs and new drug launches.
AstraZeneca, Bristol Myers Squibb Reportedly Eyeing $400 Billion Merger Deal
UK pharmaceutical giant AstraZeneca and its US rival Bristol Myers Squibb are reportedly in discussions for a massive $400 billion merger. If realized, this megadeal would create one of the world's largest drugmakers, significantly reshaping the global pharmaceutical landscape.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.